No abstract

GABA(A) receptors are the major inhibitory neurotransmitter receptors in the brain and are the site of action of many clinically important drugs. These receptors are composed of five subunits that can belong to eight different subunit classes. Depending on their subunit composition, these receptors exhibit distinct pharmacological and electrophysiological properties. Recent studies on recombinant and native GABA(A) receptors suggest the existence of far more receptor subtypes than previously assumed. Thus, receptors composed of one, two, three, four, or five different subunits might exist in the brain. Studies on the regional, cellular and subcellular distribution of GABA(A) receptor subunits, and on the co-localization of these subunits at the light and electron microscopic level for the first time provide information on the distribution of GABA(A) receptor subtypes in the brain. These studies will have to be complemented by electrophysiological and pharmacological studies on the respective recombinant and native receptors to finally identify the receptor subtypes present in the brain. The distinct cellular and subcellular location of individual receptor subtypes suggests that they exhibit specific functions in the brain that can be selectively modulated by subtype specific drugs. This conclusion is supported by the recent demonstration that different GABA(A) receptor subtypes mediate different effects of benzodiazepines. Together, these results should cause a revival of GABA(A) receptor research and strongly stimulate the development of drugs with a higher selectivity for alpha2-, alpha3-, or alpha5-subunit-containing receptor subtypes. Such drugs might exhibit quite selective clinical effects.

No abstract

IL-1␤ and its endogenous receptor antagonist (IL-1RaIL-1␤ appears to be involved in neuronal network excitability because it affects the turnover and release of various neurotransmitters (1) and the expression of neuropeptides and neurotrophic factors (3-5) and alters synaptic transmission and ionic currents (6-9) in several rodent forebrain regions.Convulsant stimuli increase the production of IL-1␤, its naturally occurring receptor antagonist (IL-1Ra), and IL-1R type I and II predominantly in glia in rodent central nervous system within hours of seizure induction (10-15).We recently showed that IL-1␤ prolongs hippocampal electroencephalographic (EEG) seizures in a N-methyl-D-aspartate receptor-dependent manner, and this action was blocked by .In this study, we investigated whether IL-1Ra has anticonvulsant properties in rodents. We found that intracerebral application of recombinant IL-1Ra or its endogenous overexpression in astrocytes potently inhibited behavioral and EEG seizures induced by bicuculline methiodide in mice. This effect was mediated specifically by IL-1R type I, because IL-1Ra was ineffective in knockout mice deficient in these receptors.Thus, the functional interaction between brain-born IL-1␤ and IL-1Ra during seizures, (i) may play a critical role in the physiopathological functions of IL-1␤, and (ii) may significantly affect the maintenance and spread of seizures. Materials and MethodsAnimals. Procedures involving animals and their care were conducted in conformity with institutional guidelines in compliance with national and international laws and policies (4D. L. N. 116, Gazzetta Ufficiale, supplement 40, 18-2-1992 and European

No abstract

No abstract

Tissue expression and distribution of the high-conductance Ca(2+)-activated K+ channel Slo was investigated in rat brain by immunocytochemistry, in situ hybridization, and radioligand binding using the novel high-affinity (Kd 22 pM) ligand [3H]iberiotoxin-D19C ([3H]IbTX-D19C), which is an analog of the selective maxi-K peptidyl blocker IbTX. A sequence-directed antibody directed against Slo revealed the expression of a 125 kDa polypeptide in rat brain by Western blotting and precipitated the specifically bound [3H]IbTX-D19C in solubilized brain membranes. Slo immunoreactivity was highly concentrated in terminal areas of prominent fiber tracts: the substantia nigra pars reticulata, globus pallidus, olfactory system, interpeduncular nucleus, hippocampal formation including mossy fibers and perforant path terminals, medial forebrain bundle and pyramidal tract, as well as cerebellar Purkinje cells. In situ hybridization indicated high levels of Slo mRNA in the neocortex, olfactory system, habenula, striatum, granule and pyramidal cell layer of the hippocampus, and Purkinje cells. The distribution of Slo protein was confirmed in microdissected brain areas by Western blotting and radioligand-binding studies. The latter studies also established the pharmacological profile of neuronal Slo channels. The expression pattern of Slo is consistent with its targeting into a presynaptic compartment, which implies an important role in neural transmission.

No abstract